Development of cancer vaccines to activate cytotoxic T lymphocytes

Expert Opinion on Biological Therapy

Volumn 5, Issue 4, 2005, Pages 555-563

  Durrant, L G ^a   Ramage, J M ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NONE

Author keywords

Cancer vaccines; CD8; CTL; Dendritic cells; Tolerance; Tumour associated antigens

Indexed keywords

ANGIOPOIETIN RECEPTOR; ANTIBODY; ANTIGEN; CANCER VACCINE; CD64 ANTIGEN; CD8 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DNA; DNA VACCINE; EPITOPE; FC RECEPTOR; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MANNOSE RECEPTOR; MONOCLONAL ANTIBODY B11; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOKINE THERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DEPLETION; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; TARGET CELL DESTRUCTION; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TECHNOLOGY, PHARMACEUTICAL;

EID: 17844408717     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.4.555     Document Type: Review

References (65)

1. ROSENBERG SA: A New era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity (1999) 10(3):281-287.
2. STEITZ J, BKUCK J, LENZ J, KNOP J, TUTING T: Depletion of CD25+CD4+ T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon α-induced, CD8+ T-cell-dependent immune defense of B16 melanoma. Cancer Res. (2001) 61:8643-8646.
3. GOLGHER D, JONES E, POWRIE F, ELLIOTT T, GALLIMORE A: Depletion of CD25+ regulatory cells uncovers immune responses to shared tumor rejection antigens. Eur. J. Immunol. (2002) 32:3267-3275.
4. SLIFKA MK, WHITTON JL: Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR. Nat. Immunol. (2001) 2(8):711-717.
5. KUMARAGURU U, SUVAS S, BISWAS PS, AZKUR AK, ROUSE BT: Concomitant helper response rescues otherwise low avidity CD8+ memory CTLs to become efficient effectors in vivo. J. Immunol. (2004) 172:3719-3724.
6. + T lymphocytes induced by peptide immunization: an ex vivo analysis. Int. Immunol. (1998) 10:1273-1279.
7. ALAM SM, TRAVERS PJ, WUNG JL et al.: T-cell-receptor affinity and thymocyte positive selection. Nature (1996) 381:616-620.
8. FRENCH RR, CHAN HT, TUTT AL, GLENNIE MJ: Improved immunogenicity if a self tumor antigen by covalent linkage to CD40 ligand. Int. J. Cancer (1999) 108:896-703.
9. ORLEANS-LINDSY JK, DERU A, CRAIG JI, PRENTICE HG, LOWDELL MW: In vitro co-stimulation with anti-CD28 synergizes with IL12 in the generation of T cell immune responses to leukuemic cells; a strategy for ex-vivo generation of CTLs for immunotherapy. Clin. Exp. Immunol. (2003) 133:467-475.
10. XU D, GU P, PAN PY et al.: NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-IBB costimulation. Int. J. Cancer (2004) 109:499-506.
11. LUSTGARTEN J, DOMINGUEZ AL, CUADROS C: The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. (2004) 34:752-761.
12. OH S, HODGE JW, AHLERS JD, BURKE DS, SCHLOM J, BERZOFSKY JA: Selective induction of high avidity CTL by altering the balance of signals for APC. J. Immunol. (2003) 170:2523-2530.
13. GUERMONPREZ P, SAVEANU L, KLEIJMEER M et al.: ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature (2003) 425(6956):397-402.
14. HOUDE M, BERTHOLET S, GAGNON E et al.: Phagosomes are competent organelles for antigen cross presentation. Nature (2003) 425(6956):402-406.
15. VALMORI D, GILEADI U, SERVIS C et al.: Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. (1999) 189:895-906.
16. GNJATIC S, JAGER E, CHEN W et al.: CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc. Natl. Acad. Sci. USA (2002) 99:11813-11818.
17. HART I, COLACO C: Immunotherapy: fusion induces tumour rejection. Nature (1997) 388:626-627.
18. GONG J, CHEN D, KASHIWABA M, KUFE M: Induction of anti-tumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. (1997) 3:558-561.
19. KRAUSE SW, NEUMANN C, SORURI A, MAYER S, PETERS JH, ANDREESEN R: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J. Immunother. (2002) 25:421-428.
20. KIKUCHI T, AKASAKI Y, IRIE M, HOMMA S, ABE T, OHNO T: Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. (2001) 50:337-344.
21. ROSENBERG SA, DUDLEY ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumour lymphocytes. Proc. Natl. Acad. Sci. USA (2004) 101(Suppl. 2):14639-14645.
22. MCKAY PF, BAROUCH DH, SANTRA S et al.: Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur. J. Immnnol. (2004) 34:1011-1020.
23. PALMOWSKI MJ, CHOI EM, HERMANS IF et al.: Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. (2002) 168:4391-4398.
24. LONCHAY C, VAN DER BRUGGEN P, CONNEROTTE T et al.: Correlation between tumour regression and T cell responses in melanoma patients vaccinated with MAGE antigen. Proc. Natl. Acad. Sci. USA (2004) 101:14631-14638.
25. BERZOFSKY JA, AHLERS JD, BELYAKOV IM: Strategies for designing and optimising new generation vaccines. Nat. Rev. Immunol. (2001) 1:209-217.
26. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. (1998) 4(3):321-327.
27. PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100:8372-8377.
28. SMITH CL, DUNBAR PR, MIRZA F et al.: Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer (2005) 113:259-266.
29. PALMOWSK MJ, SALIO M, HERMANS IF, DUNBAR PR, CERUNDOLO V: The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol. Rev. (2002) 188:155-163.
30. RIDGWAY D: The first 1000 dendritic cell vaccines. Cancer Invest. (2003) 21:873-886.
31. SRIVASTAVA P: Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. (2002) 20:395-425.
32. BELLI F, TESTORI A, RIVOLTINI L et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. (2002) 20:4169-4180.
33. DATTA SK, RAZ E: Induction of antigen cross-presentation by Toll receptors. Springer Semin. Immunopathol. (2005) 26(3):247-255.
34. HE LZ, RAMAKRISHNA V, CONNOLLY JE et al.: A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin. Cancer Res. (2004) 10:1920-1927.
35. RAMAKRISHNA V, TREML JF, VITALE L et al.: Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol. (2004) 172:2845-2852,
36. REGNAULT A, LANKAR D, LACABANNE V et al.: Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I restricted antigen presentation after immune complex internalization. J. Exp. Med. (1999) 189:371-380.
37. AUSTIN EB, ROBINS RA, DURRANT LG, PRICE MR, BALDWIN RW: Human monoclonal antiidiotypic antibody to the tumour associated antibody 791T/36. Immunology (1989) 67:525-530.
38. AUSTIN EB, ROBINS RA, BALDWIN RW, DURRANT LG: Induction of delayed-hypcrsensitivity to human tumor-cells with a human monoclonal antiidiotypic antibody. J. Natl. Cancer Inst. (1991) 83(17):1245-1248.
39. ROBINS RA, DENTON GW, HARDCASTLE JD, AUSTIN EB, BALDWIN RW, DURRANT LG: Antitumor immune-response and interleukin-2 production induced in colorectal-cancer patients by immunisation with human monoclonal antiidiotypic antibody. Cancer Res. (1991) 51(19):5425-5429.
40. DENTON GW, ROBBINS RA, DURRANT LG et al.: Cell-mediated response in vitro after immunization of colorectal cancer patients with a human monoclonal antiidiotypic antibody. Gut (1991) 32(5):A557-A557.
41. DURRANT LG, BUCKLEY TJ, DENTON GW et al.: Enhanced cell mediated tumour killing in patients immunised with human monoclonal antiidiotypic antibody 105AD7. Cancer Res. (1994) 54:4837-4840.
42. DURRANT LG, ARMSTRONG CM, BUCKLEY D et al.: A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin. Cancer Res. (2000) 62(2):422-430.
43. DURRANT LG, SPENDLOVE I, BUCKLEY DJ, ROBINS RA: 105AD7 cancet vaccine stimulates anti-tumour helper and cytotoxic T cell responses in HLA-A1,3,24 and HLA-DR 1,3,7 colorectal cancer patients. Int. J. Cancer (2000) 85(1):87-92.
44. SPENDLOVE I, LI L, CARMICHAEL J, DURRANT LG: Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res. (1999) 59(10):2282-2286.
45. SPENDLOVE I, LI L, POTTER V et al.: A therapeutic human anti-idiotypic antibody (105AD7) mimics CD55 (decay accelerating factor) in three distinct regions. Eur. J. Immunol. (2000) 30:2944-2953.
46. MAXWELL-ARMSTRONG CA, DURRANT LG, ROBINS RA et al.: Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotype monoclonal antibody 105AD7. Gut (1999) 45:593-598.
47. MAXWELL-ARMSTRONG CA, DURRANT LG, SCHOLEFIELD JH: Immunotherapy for colorectal cancer. Am. J. Surg. (1999) 177(4):344-348.
48. MAXWELL-ARMSTRONG CA, DURRANT LG, RUCKLEY TJ et al.: Randomized double-blind Phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br. J. Cancer (2001) 84(11):1443-1446.
49. AMIN S, ROBINS RA, MAXWELL-ARMSTRONG C, SCHOLEFIELD J, DURRANT LG: Vaccine induced apoptosis: a novel clinical trial endpoint? Cancer Res. (2000) 63:3132-3136.
50. DURRANT LG, PARSONS T, MOSS R et al.: Human anti-idiotypic antibodies can be good immunogens as they target Fc receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses. Int. J. Cancer (2001) 92:414-420.
51. DURRANT LG, DENTON GW, JACOBS E et al.: An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumors. Int. J. Cancer (1992) 50(5):811-816.
52. PARSONS T, SPENDLOVE I, NIRULA R et al.: A novel CEA vaccine stimulates T cell proliferation, gammaIFN secret and CEA specific CTL responses. Vaccine (2004) 22(25-26):3487-3494.
53. SCHUURHUIS DH, IOAN-FACSINAY A, NAGELKERKEN B et al.: Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J. Immunol. (2002) 168(5):2240-2246.
54. YOU Z, HESTER J, ROLLINS L et al.: A retrogen strategy for presentation of an intracellular tumour antigen as an exogenous antigen by dendritic cells induces potent antitumour T helper and CTL responses. Cancer Res. (2001) 61:197-205.
55. YOU Z, HUANG X, HESTER J, TOH HC, CHEN SY: Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. (2001) 61:3704-3711.
56. RAMAGE JM, METHERINGHAM R, CONN A et al.: Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. Int. J. Cancer (2004) 110:245-250.
57. RAMAGE JM, METHERINGHAM R, MOSS RS et al.: DNA-Fc Fusion Vaccine targeting the endothelial antigen Tie-2. Br. J. Cancer (2003) 88(Suppl. 1):S38.
58. TRAN R, HAND PH, GREINER JW, PESTKA S, SCHOLM J: Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons. J. Interferon Res. (1988) 8:75-88.
59. DONG H, STROME SE, SALOMAO D et al.: Tumor-associated B7-Hi promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. (2002) 8(8):793-800.
60. ROBERTS AI, LEE L, SCHWARZ E et al.: NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. (2001) 167:5527-5530.
61. NIETHAMMER AG, XIANG R, RUEHLMANN JM et al.: Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res. (2001) 61:6178-6184.
62. GARNET CT, PALENA C, CHAKARBORTY M et al.: Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. (2004) 64:7985-7994.
63. CHAKARBORTY M, ABRAMS SI, COLEMAN CN et al.: External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine mediated T-cell killing. Cancer Res. (2004) 64:4328-4337.
64. MACHIELS JP, REILLY RT, EMENS LA et al.: Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumour immune responses of granulocyte/ macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerised mice. Cancer Res. (2001) 61:3689-3697.
65. HILL SC, YOUDE SJ, MAN S et al.: Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J. Immunol. (2005) 174:41-50.